A protocol for isolation and culture of mesenchymal stem …

We explain a protocol for straightforward isolation and culture of mesenchymal stem cells (MSCs) from mouse bone marrow (BM) to supply researchers with a method that can be applied in cell biology and tissue engineering with minimal requirements. Our protocol is mainly on the basis of the frequent medium change in primary culture and diminishing the trypsinization time. Mouse mesenchymal stem cells are generally isolated from an aspirate of BM harvested from the tibia and femoral marrow compartments, then cultured in a medium with Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) for 3 h in a 37 degrees C-5% CO(2) incubator

Read more
Mesoblast has long been the one poster child for stem cell therapy. Now Cynata and other ASX stocks have e … – Stockhead

Stem cell therapy, sometimes called regenerative medicine, is one of the most exciting areas of the life sciences sector right now. Since the pandemic, the sector has emerged into the publics spotlight with new developments in mRNA-based vaccines and therapies. Nasdaq is the obvious breeding ground for world-class stem cell companies with the likes of Moderna and BioNTech, and lesser known names like Anavex and Enochian

Read more
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell…

CRANFORD, N.J., Dec. 6, 2021 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies,today announced that it has completed patient enrollment in its Pivotal Phase 3 trial of I/ONTAK, an engineered IL-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL)

Read more
American CryoStem Announces the Addition of John Schwartz, PhD to Its Advisory Board – Stockhouse

EATONTOWN, NJ / ACCESSWIRE / November 23, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a leading clinical-stage biotechnology developer of adipose tissue-based cellular technologies for Regenerative and Personalized Medicine announced today that it has added John "Jay" Schwartz, PhD to its Scientific and Medical Advisory Board.

Read more
KU holds session on dynamics of health and research | The Academia – The Academia Mag

The Department of Physiology University of Karachi arranged an Annual Research Talk (ART) 2020-2021 a scientific event for the faculty members and students. The theme of the event was Dynamics of Health and Research. The event included poster competition among students in two categories of thematic posters and research posters along with three faculty presentations by Dr Mufzala Shamim, Dr Faizan Mirza, and Hafiz Muhammad Usman

Read more
Dutch stem cell biotech Neuroplast secures 10 million (US$ 11.5 million) in Series B funding to further advance its transformative stem cell therapy…

GELEEN, Netherlands, Nov. 17, 2021 /PRNewswire/ -- Dutch clinical phase biotech Neuroplast raised a total of 10 million (US$ 11.5 million) in funding from investors Lumana Invest, Brightlands Venture Partners, LIOF, and from the Innovation Credit from the Netherlands Enterprise Agency, to further advance the clinical development of a transformative treatment for Traumatic Spinal Cord Injury (TSCI). Neuroplast will use this Series B funding to obtain conditional EMA market approval for its Neuro-Cells stem cell therapy

Read more